It should not be a premium, as the company already trades. This will add liquidity and access to additional capital in the future where required.
I dont really know if this is required, but the leadership at Telix have been on point at every turn so I am going to defer to their judgement. Ordinarily, biotech companies that have done in the past is usually a big waste of time and shareholder's funds. I know that ResMed are listed, but then COH and CSL are not, so not an absolute requirement,
Ann: Telix Plans U.S. Registered Public Offering and Listing, page-28
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.46 |
Change
0.560(2.68%) |
Mkt cap ! $7.182B | |||
| Open | High | Low | Value | Volume |
| $21.06 | $21.54 | $20.77 | $14.04M | 660.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3400 | $21.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.48 | 1645 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |